Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 54 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
SUPERBIOTICS from Eghezée, company number BE0719267569, closed financial year 2025 with a result of € -93,577 after tax. For that financial year SUPERBIOTICS recorded a gross margin of € 147,182 and equity of € -9,693. Compared with financial year 2024, the result moved from € -71,531 to € -93,577. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ -9,693
▼ € 93,577 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -93,577
▼ 31 % more loss than in 2024
Profit after tax over the fiscal year.
€ 45,382
▼ 19% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -173,953.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 215,245
▲ 299% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 68,089
€ 30,893 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 17,032
▲ 160% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 23,701
▲ 22% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 11,772 | € 73,388 | - | - | |
| Gross margin | € -3,576 | € 43,308 | € -12,008 | € 147,182 | ▲ € 159,189 |
| Profit after taxes | € -4,015 | € 43,065 | € -71,531 | € -93,577 | ▼ € 22,046 |
| Equity | € -37,651 | € 5,414 | € 83,884 | € -9,693 | ▼ € 93,577 |
| Total debts | € 94,214 | € 217,491 | € 25,947 | € 193,677 | ▲ € 167,730 |
| Cash | € 1,514 | € 216 | € 56,185 | € 45,382 | ▼ 19% |
| Retained profit | € -50,051 | € -8,846 | € -80,376 | € -173,953 | ▼ € 93,577 |
| Bank debt | € 0 | € 0 | € 0 | € 68,089 | |
| Balance sheet total | € 56,563 | € 222,905 | € 109,831 | € 183,985 | ▲ 68% |
Key figures of SUPERBIOTICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SUPERBIOTICS?
What happened at SUPERBIOTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 93,577. filed late Source: NBB ↗
- New establishment in Gembloux. KBO
- New establishment in Eghezée. KBO
- Start of the company according to the CBE. KBO
In short
From € 4,015 loss in 2022 to € 93,577 loss in 2025.
Paid € 168 in corporate taxes since 2022.
Best year ever: 2023, with € 43,065 profit.
A new publication or filing at SUPERBIOTICS? We notify you, reason included.
Follow SUPERBIOTICSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind SUPERBIOTICS is Jehan Lienart van Lidth de Jeude.
Directors
According to the 2025 annual accounts
Jehan Lienart van Lidth de Jeude
Director
Establishments
Establishment units
Physical locations of this company
Rue Louis Allaert,Noville 9
5310 Eghezée
Rue Jean Sonet,Isnes 29
5032 Gembloux
Active since 17 June 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0719.267.569
- VAT number
- BE 0719.267.569
- Registered office
- Rue Louis Allaert,Noville 9, 5310 Eghezée
- Names & denominations
- SUPERBIOTICS · Vésale Superbiotics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 January 2019
- Peppol
- Active · Active since 5 Feb 2026
- Contact
- [email protected]
- Activities · NACE
Vervaardiging van andere voedingsmiddelen, neg
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van overige farmaceutische producten
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Groothandel in farmaceutische en medische artikelen